Oxymatrine attenuates hepatic steatosis in non-alcoholic fatty liver disease rats fed with high fructose diet through inhibition of sterol regulatory element binding transcription factor 1 (Srebf1) and activation of peroxisome proliferator activated receptor alpha (Pparα)

European Journal of Pharmacology

Volumn 714, Issue 1-3, 2013, Pages 89-95

  Shi, Li Juan ^a   Shi, Lei ^b   Song, Guang Yao ^c   Zhang, He Fang ^a   Hu, Zhi Juan ^c   Wang, Chao ^c   Zhang, Dong Hui ^c  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b Hebei Chemical Medicine Vocational Technology College   (China)

^c HEBEI GENERAL HOSPITAL   (China)

Author keywords

Fatty acid oxidation; Fatty acid synthesis; Liver steatosis; Oxymatrine

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; AMINOTRANSFERASE; CARNITINE PALMITOYLTRANSFERASE I; CARNITINE PALMITOYLTRANSFERASE I A; CHOLESTEROL; FATTY ACID; FATTY ACID SYNTHASE; FRUCTOSE; OXYMATRINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALORIC INTAKE; CARBOHYDRATE DIET; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOWN REGULATION; DRUG DOSE REGIMEN; DYSLIPIDEMIA; ENZYME ACTIVITY; FATTY ACID BLOOD LEVEL; FATTY ACID OXIDATION; FATTY LIVER; GENE EXPRESSION; HISTOPATHOLOGY; LIPID BLOOD LEVEL; LIPID LIVER LEVEL; LIPID METABOLISM; LIPID STORAGE; LIPID TRANSPORT; LIPOGENESIS; LIVER FUNCTION TEST; LIVER WEIGHT; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; SOPHORA FLAVESCENS; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; LIVER STEATOSIS; OXYMATRINE;

ALKALOIDS; ANIMALS; BODY WEIGHT; DIET; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSLIPIDEMIAS; ENERGY INTAKE; FATTY ACIDS; FATTY LIVER; FRUCTOSE; GENE EXPRESSION REGULATION; LIVER; MALE; OXIDATION-REDUCTION; PPAR ALPHA; QUINOLIZINES; RATS; RATS, WISTAR; RNA, MESSENGER; SIGNAL TRANSDUCTION; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

EID: 84879829639     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.06.013     Document Type: Article

References (38)

1. Bieber, L.L., Abraham, T., Helmrath, T., 1972. A rapid spectrophotometric assay for carnitine palmitoyltransferase. Analytical Biochemistry 50, 509-518.
2. Cherkaoui-Malki, M., Surapureddi, S., El-Hajj, H.I., Vamecq, J., Andreoletti, P., 2012. Hepatic steatosis and peroxisomal fatty acid beta-oxidation. Current Drug Metabolism 13, 1412-1421.
3. Chirala, S.S., Wakil, S.J., 2004. Structure and function of animal fatty acid synthase. Lipids 39, 1045-1053. (Pubitemid 40129046)
4. Chitturi, S., Farrell, G.C., Hashimoto, E., Saibara, T., Lau, G.K., Sollano, J.D., 2007. Nonalcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. Journal of Gastroenterology and Hepatology 22, 778-787. (Pubitemid 46915352)
5. Clavey, V., Copin, C, Mariotte, M.C., Bauge, E., Chinetti, G., Fruchart, J., Fruchart, J.C., Dallongeville, J., Staels, B., 1999. Cell culture conditions determine apolipopro-tein CIII secretion and regulation by fibrates in human hepatoma HepG2 cells. Cellular Physiology and Biochemistry 9, 139-149. (Pubitemid 29439099)
6. Crescenzo, R., Bianco, F., Falcone, I., Coppola, P., Liverini, G., Iossa, S., 2012. Increased hepatic de novo lipogenesis and mitochondrial efficiency in a model of obesity induced by diets rich in fructose. European Journal of Nutrition 52, 537-545.
7. Day, C.P., James, O.F., 1998. Steatohepatitis: a tale of two "hits,"? Gastroenterology 114, 842-845.
8. Ferre, P., Foufelle, F., 2010. Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes, Obesity and Metabolism 12 (Suppl. 2), 83-92.
9. Fiebig, R., Griffiths, M.A., Gore, M.T., Baker, D.H., Oscai, L, Ney, D.M., Ji, LL, 1998. Exercise training down-regulates hepatic lipogenic enzymes in meal-fed rats: fructose versus complex-carbohydrate diets. Journal of Nutrition 128, 810-817. (Pubitemid 28225509)
10. Folch, J., Lees, M., Sloane Stanley, G.H., 1957. A simple method for the isolation and purification of total lipids from animal tissues. Journal of Biological Chemistry 226, 497-509.
11. Frederico, M.J., Vitto, M.F., Cesconetto, P.A., Engelmann, J., De Souza, D.R., Luz, G., Pinho, R.A., Ropelle, E.R., Cintra, D.E., De Souza, CT., 2011. Short-term inhibition of SREBP-1c expression reverses diet-induced non-alcoholic fatty liver disease in mice. Scandinavian Journal of Gastroenterology 46, 1381-1388.
12. Gomez-Zorita, S., Fernandez-Quintela, A., Macarulla, M.T., Aguirre, L., Hijona, E., Bujanda, L, Milagro, F., Martinez, JA, Portillo, M.P., 2012. Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress. British Journal of Nutrition 107, 202-210.
13. Hashimoto, T., Fujita, T., Usuda, N., Cook, W., Qi, C, Peters, J.M., Gonzalez, F.J., Yeldandi, A.V., Rao, M.S., Reddy, J.K., 1999. Peroxisomal and mitochondrial fatty acid beta-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor alpha and peroxisomal fatty acyl-CoA oxidase. Genotype correlation with fatty liver phenotype. Journal of Biological Chemistry 274, 19228-19236.
14. Hong-Li, S., Lei, L., Lei, S., Dan, Z., De-Li, D., Guo-Fen, Q., Yan, L., Wen-Feng, C, Bao-Feng, Y., 2008. Cardioprotective effects and underlying mechanisms of oxymatrine against ischemic myocardial injuries of rats. Phytotherapy Research 22, 985-989.
15. Huang, M., Hu, Y.Y., Dong, X.Q., Xu, Q.P., Yu, W.H., Zhang, Z.Y., 2012. The protective role of oxymatrine on neuronal cell apoptosis in the hemorrhagic rat brain. Journal of Ethnopharmacology 143, 228-235.
16. Huang, X.S., Zhao, S.P., Bai, L., Hu, M., Zhao, W., Zhang, Q., 2009. Atorvastatin and fenofibrate increase apolipoprotein AV and decrease triglycerides by up-regulating peroxisome proliferator-activated receptor-alpha. British Journal of Pharmacology 158, 706-712.
17. Jiang, H., Meng, F., Li, J., Sun, X., 2005. Anti-apoptosis effects of oxymatrine protect the liver from warm ischemia reperfusion injury in rats. World Journal of Surgery 29, 1397-1401. (Pubitemid 41712670)
18. Lazo, M., Clark, J.M., 2008. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Seminars in Liver Disease 28, 339-350.
19. Lu, LG., Zeng, M.D., Mao, Y.M., Li, J.Q., Wan, M.B., Li, C.Z., Chen, C.W., Fu, Q.C., Wang, J.Y, She, W.M., Cai, X., Ye, J., Zhou, X.Q., Wang, H., Wu, S.M., Tang, M.F., Zhu, J.S., Chen, W.X., Zhang, H.Q., 2003. Oxymatrine therapy for chronic hepatitis B: a randomized double-blind and placebo-controlled multi-center trial. World Journal of Gastroenterology 9, 2480-2483. (Pubitemid 37461252)
20. Munday, M.R., 2002. Regulation of mammalian acetyl-CoA carboxylase. Biochemical Society Transactions 30, 1059-1064. (Pubitemid 36002406)
21. Musso, G., Gambino, R., Cassader, M., 2009. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Progress in Lipid Research 48, 1-26.
22. Nagai, Y., Nishio, Y., Nakamura, T., Maegawa, H., Kikkawa, R., Kashiwagi, A., 2002. Amelioration of high fructose-induced metabolic derangements by activation of PPARalpha. American Journal of Physiology - Endocrinology and Metabolism 282, E1180-1190. (Pubitemid 34654734)
23. Nomura, K., Yamanouchi, T., 2012. The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease. Journal of Nutritional Biochemistry 23, 203-208.
24. Petta, S., Muratore, C, Craxi, A., 2009. Non-alcoholic fatty liver disease pathogenesis: the present and the future. Digestive and Liver Disease 41, 615-625.
25. Ren, L.P., Chan, S.M., Zeng, X.Y., Laybutt, D.R., Iseli, T.J., Sun, R.Q., Kraegen, E.W, Cooney, G.J., Turner, N., Ye, J.M., 2012a. Differing endoplasmic reticulum stress response to excess lipogenesis versus lipid oversupply in relation to hepatic steatosis and insulin resistance. PLoS One 7, e30816.
26. Ren, L.P., Song, G.Y., Huo, LJ., Liu, N., Chen, S.C., 2012b. Effects of oxymatrine on high-fructose-feeding-induced fatty liver and endoplasmic reticulum stress in rats. Journal of China Medical University 41, 892-895.
27. Roglans, N., Vila, L., Farre, M., Alegret, M., Sanchez, R.M., Vazquez-Carrera, M., Laguna, J.C., 2007. Impairment of hepatic STAT-3 activation and reduction of PPARalpha activity in fructose-fed rats. Hepatology 45, 778-788. (Pubitemid 46450629)
28. Schoonjans, K., Peinado-Onsurbe, J., Lefebvre, A.M., Heyman, R.A., Briggs, M., Deeb, S., Staels, B., Auwerx, J., 1996. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. The EMBO Journal 15, 5336-5348. (Pubitemid 26336216)
29. Sheng, L., Cho, K.W., Zhou, Y., Shen, H., Rui, L., 2011. Lipocalin 13 protein protects against hepatic steatosis by both inhibiting lipogenesis and stimulating fatty acid beta-oxidation. Journal of Biological Chemistry 286, 38128-38135.
30. Staels, B., Vu-Dac, N., Kosykh, V.A., Saladin, R., Fruchart, J.C., Dallongeville, J., Auwerx, J., 1995. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. Journal of Clinical Investigation 95, 705-712.
31. Thorburn, A.W., Storlien, L.H., Jenkins, A.B., Khouri, S., Kraegen, E.W., 1989. Fructose-induced in vivo insulin resistance and elevated plasma triglyceride levels in rats. American Journal of Clinical Nutrition 49, 1155-1163. (Pubitemid 19169675)
32. Wu, X.N., Wang, G.J., 2004. Experimental studies of oxymatrine and its mechanisms of action in hepatitis B and C viral infections. Chinese Journal of Digestive Diseases 5, 12-16. (Pubitemid 38401244)
33. Zabala, A., Churruca, I., Macarulla, M.T., Rodriguez, V.M., Fernandez-Quintela, A., Martinez, J.A., Portillo, M.P., 2004. The trans-10, cis-12 isomer of conjugated linoleic acid reduces hepatic triacylglycerol content without affecting lipogenic enzymes in hamsters. British Journal of Nutrition 92, 383-389. (Pubitemid 40277059)
34. Zammit, V.A., 2008. Carnitine palmitoyltransferase 1: central to cell function. International Union of Biochemistry and Molecular Biology (IUBMB) Life 60, 347-354.
35. Zeng, X.Y., Zhou, X., Xu, J., Chan, S.M., Xue, C.L., Molero, J.C., Ye, J.M., 2012. Screening for the efficacy on lipid accumulation in 3T3-L1 cells is an effective tool for the identification of new anti-diabetic compounds. Biochemical Pharmacology 84, 830-837.
36. Zhang, Y., Piao, B., Zhang, Y., Hua, B., Hou, W., Xu, W., Qi, X., Zhu, X., Pei, Y., Lin, H., 2011. Oxymatrine diminishes the side population and inhibits the expression of beta-catenin in MCF-7 breast cancer cells. Medical Oncology 28 (Suppl. 1), S99-107.
37. Zhao, J., Yu, S., Tong, L., Zhang, F., Jiang, X., Pan, S., Jiang, H., Sun, X., 2008. Oxymatrine attenuates intestinal ischemia/reperfusion injury in rats. Surgery Today 38, 931-937.
38. Zheng, L., Lv, G.C., Sheng, J., Yang, Y.D., 2010. Effect of miRNA-10b in regulating cellular steatosis level by targeting PPAR-alpha expression, a novel mechanism for the pathogenesis of NAFLD. Journal of Gastroenterology and Hepatology 25, 156-163.